Patient characteristics
| Characteristic . | No. of patients . |
|---|---|
| Sex | N = 47 |
| Male | 25 |
| Female | 22 |
| Age, y | |
| Median | 59 |
| Range | 27-84 |
| > 60 | 23 |
| ECOG Performance Status | |
| 0 | 20 |
| 1 | 23 |
| 2 | 4 |
| Extent of disease at enrollment | |
| Stage II | 2 |
| Stage III | 11 |
| Stage IV | 34 |
| Bone marrow involvement | 14 |
| Elevated LDH | 26 |
| Primary Diagnosis | N = 47 |
| PTCL, unspecified or NOS | 27 (57%) |
| Angioimmunoblastic* | 7 (15%) |
| Anaplastic large T-cell, ALK pos | 2 (4%) |
| Anaplastic large T-cell, ALK neg | 2 (4%) |
| Primary cutaneous anaplastic large T-cell | 2 (4%) |
| Cutaneous γδ T-cell | 2 (4%) |
| Hepatosplenic PTCL | 1 (2%) |
| Enteropathy associated T-cell lymphoma | 1 (2%) |
| PTCL, unspecified of the skin | 1 (2%) |
| CD30 lymphoproliferative disorder | 1 (2%) |
| Diffuse large B-cell lymphoma* | 1 (2%) |
| Characteristic . | No. of patients . |
|---|---|
| Sex | N = 47 |
| Male | 25 |
| Female | 22 |
| Age, y | |
| Median | 59 |
| Range | 27-84 |
| > 60 | 23 |
| ECOG Performance Status | |
| 0 | 20 |
| 1 | 23 |
| 2 | 4 |
| Extent of disease at enrollment | |
| Stage II | 2 |
| Stage III | 11 |
| Stage IV | 34 |
| Bone marrow involvement | 14 |
| Elevated LDH | 26 |
| Primary Diagnosis | N = 47 |
| PTCL, unspecified or NOS | 27 (57%) |
| Angioimmunoblastic* | 7 (15%) |
| Anaplastic large T-cell, ALK pos | 2 (4%) |
| Anaplastic large T-cell, ALK neg | 2 (4%) |
| Primary cutaneous anaplastic large T-cell | 2 (4%) |
| Cutaneous γδ T-cell | 2 (4%) |
| Hepatosplenic PTCL | 1 (2%) |
| Enteropathy associated T-cell lymphoma | 1 (2%) |
| PTCL, unspecified of the skin | 1 (2%) |
| CD30 lymphoproliferative disorder | 1 (2%) |
| Diffuse large B-cell lymphoma* | 1 (2%) |
Two patients were evaluable for toxicity assessment and excluded from response assessment: 1 with angioimmunoblastic T-cell lymphoma found to be ineligible for enrollment after the first dose and 1 whose T-cell lymphoma was reclassified as DLBCL.